GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » ROC (Joel Greenblatt) %

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) ROC (Joel Greenblatt) % : -2,357.60% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sonnet BioTherapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2,357.60%.

The historical rank and industry rank for Sonnet BioTherapeutics Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:

SONN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12234.64   Med: -9047.39   Max: -5877.64
Current: -5877.64

During the past 5 years, Sonnet BioTherapeutics Holdings's highest ROC (Joel Greenblatt) % was -5877.64%. The lowest was -12234.64%. And the median was -9047.39%.

SONN's ROC (Joel Greenblatt) % is ranked worse than
88.39% of 1464 companies
in the Biotechnology industry
Industry Median: -329.055 vs SONN: -5877.64

Sonnet BioTherapeutics Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Sonnet BioTherapeutics Holdings ROC (Joel Greenblatt) % Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings ROC (Joel Greenblatt) % Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
ROC (Joel Greenblatt) %
- -6,354.38 -11,003.07 -12,234.64 -7,091.70

Sonnet BioTherapeutics Holdings Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7,648.38 -8,255.01 -6,117.19 -6,075.95 -2,357.60

Competitive Comparison of Sonnet BioTherapeutics Holdings's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonnet BioTherapeutics Holdings's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Sonnet BioTherapeutics Holdings's ROC (Joel Greenblatt) % falls into.



Sonnet BioTherapeutics Holdings ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.677) - (3.339 + 0.019 + 2.094)
=-3.775

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.409) - (2.434 + 0 + 0.144)
=-1.169

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Sonnet BioTherapeutics Holdings for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.116/( ( (0.227 + max(-3.775, 0)) + (0.207 + max(-1.169, 0)) )/ 2 )
=-5.116/( ( 0.227 + 0.207 )/ 2 )
=-5.116/0.217
=-2,357.60 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sonnet BioTherapeutics Holdings  (NAS:SONN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Sonnet BioTherapeutics Holdings ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Executives
John Markey 10 percent owner 10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter officer: Chief Technical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan director, officer: Chairman, President and CEO C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney officer: Chief Medical Officer C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg officer: Chief Medical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini officer: Chief Scientific Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii officer: Chief Financial Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc 10 percent owner 918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Headlines